Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Insider Transactions

Date Name Title Type Shares Traded Price Range
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 --
Jun 18, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 --
May 22, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 40,000 $1.47
May 22, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 40,000 --
May 17, 2018
Director
Director Open market or private sale of non-derivative or derivative security 21,113 $18.94
May 17, 2018
Director
Director Other acquisition or disposition -- --
May 17, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 112,500 $1.43
May 17, 2018
Director
Director Other acquisition or disposition -- --
May 17, 2018
Director
Director Bona fide gift 362,926 --
May 17, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 250,426 $1.47
May 17, 2018
Director
Director Other acquisition or disposition -- --
May 17, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 250,426 --
May 17, 2018
Director
Director Other acquisition or disposition -- --
May 17, 2018
Director
Director Other acquisition or disposition -- --
May 17, 2018
Director
Director Other acquisition or disposition -- --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.